Sanofi-Aventis discontinues two Phase II candidates
This article was originally published in Scrip
Sanofi-Aventishas announced the discontinuation of AVE2268, an oral SGLT-2 inhibitor intended for treatment of type 2 diabetes, and surinabant, a cannabinoid 1 (CB-1) receptor antagonist for smoking cessation and obesity, due to lack of efficacy, during the release of its third quarter results. Both drugs were in Phase II trials.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.